Exane Derivatives’s Avadel Pharmaceuticals AVDL Stock Holding History

Exane Derivatives’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$81	Hold	33	–	–	﹤0.01%	725
2022 Q1	$225	Sell	33 -207	-86%	-$1.42K	﹤0.01%	953
2021 Q4	$1.94K	Sell	240 -7,582	-97%	-$69.3K	﹤0.01%	666
2021 Q3	$76.7K	Sell	7,822 -1,078	-12%	-$8.49K	0.02%	568
2021 Q2	$60.5K	Hold	8,900	–	–	0.01%	623
2021 Q1	$80.5K	Hold	8,900	–	–	0.02%	453
2020 Q4	$59.4K	Hold	8,900	–	–	0.02%	446
2020 Q3	$44.9K	Hold	8,900	–	–	0.01%	380
2020 Q2	$71.9K	Buy	+8,900	New	+$78.5K	0.02%	327

Other funds holding AVDL

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

GJL

Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

PVI

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Exane Derivatives's AVDL Position: Q2 2022 in Review

Exane Derivatives held its Avadel Pharmaceuticals (AVDL) position steady in Q2 2022 at 33 shares worth $81. The position accounts for ﹤0.01% of the portfolio, ranked #725.

Exane Derivatives first reported a position in AVDL in Q2 2020 and has held it in 9 quarters since. The position peaked at $80.5K in Q1 2021. 82 funds tracked by Wall St. Rank hold AVDL as of Q2 2022.

Exane Derivatives held 33 shares of Avadel Pharmaceuticals worth $81 as of Q2 2022.
Exane Derivatives left its Avadel Pharmaceuticals share count unchanged in Q2 2022.
Avadel Pharmaceuticals made up ﹤0.01% of Exane Derivatives's portfolio in Q2 2022, its #725 holding.
Exane Derivatives first reported a position in Avadel Pharmaceuticals in Q2 2020 and has held it in 9 quarters since.
Exane Derivatives's Avadel Pharmaceuticals position peaked at $80.5K in Q1 2021.
82 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.